AstraZeneca – Page 8

FDA Approves Amgen’s Bkemv, First Interchangeable Biosimilar to Soliris for Rare Blood Disorders ###

11 months ago talkbio0Tagged Alexion, amgen, Approved, AstraZeneca, Atypical, Atypical Hemolytic Uremic Syndrome, Biosimilars, Bkemv, Hemolytic-Uremic Syndrome, Infrequent, interchangeable, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Soliris, United States Food and Drug Administration

Bkemv, Soliris, FDA approval, Interchangeable biosimilar, Rare blood disorders, Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Amgen, AstraZeneca, Alexion Pharmaceuticals

AstraZeneca’s Oral PCSK9 Inhibitor AZD0780 Demonstrates Significant LDL-C Reduction in Phase 1 Trial

11 months ago talkbio0Tagged Administration of prophylactic statin, AstraZeneca, AZD0780, Cardiovascular Diseases, cholesterol, Hypercholesterolemia, PCSK9 Inhibitor [EPC], phase 1 trial

PCSK9 inhibitor, AZD0780, AstraZeneca, cholesterol reduction, phase 1 trial, statin therapy, hypercholesterolemia, cardiovascular disease

AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup

11 months ago talkbio0Tagged AstraZeneca, Continuance of life, Daiichi, Datopotamab, Deruxtecan, Improvement, Malignant neoplasm of lung, Nonsquamous Non-Small Cell Lung Cancer, Phase 3 trial, Sankyo, TACSTD2 gene, therapeutic autologous dendritic cells

AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer

AstraZeneca Acquires Option for SixPeaks: A Potential Breakthrough in Obesity Biotechnology

11 months ago talkbio0Tagged Acquisition (action), AstraZeneca, Biotechnology, Obesity, SixPeaks, Ventures, Versant

AstraZeneca, SixPeaks, Versant Ventures, obesity, biotechnology, acquisition, option, breakthrough.

AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China

11 months ago talkbio0Tagged AstraZeneca, Biopharma, China sales, Clinical Trials, Collaboration, development aspects, Drug Industry, Health care facility, innovation, Investments, partnerships, research

AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.

AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing

11 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, Investments, Manufacture, production, Singapore

AstraZeneca, Singapore, antibody-drug conjugate (ADC), manufacturing, investment, biotechnology, pharmaceuticals, end-to-end production, cancer treatment.

AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030

11 months ago talkbio0Tagged AstraZeneca, Biotechnology, Drug Development, Drug Industry, expansion, growth strategy, healthcare innovation, Market

AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.